Organovo Holdings (Organovo Holdings) GF Value Rank : 2 (As of Apr. 29, 2024)

View and export this data going back to 2011. Start your Free Trial

What is Organovo Holdings GF Value Rank?

Organovo Holdings has the GF Value Rank of 2.

The GF Value Rank is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Organovo Holdings's GF Value Rank

For the Biotechnology subindustry, Organovo Holdings's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Organovo Holdings's GF Value Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Organovo Holdings's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Organovo Holdings's GF Value Rank falls into.

Organovo Holdings GF Value Rank Related Terms

Thank you for viewing the detailed overview of Organovo Holdings's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Organovo Holdings (Organovo Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Organovo Holdings Inc (NAS:ONVO) » Definitions » GF Value Rank

Comparable Companies

Traded in Other Exchanges

4OR1:Germany

Address

11555 Sorrento Valley road, Suite 100, San Diego, CA, USA, 92121

Website

https://www.organovo.com

Organovo Holdings Inc is a biotechnology company, which designs and creates functional and three-dimensional human tissues for medical research and therapeutic applications. It also develops and commercializes a platform technology for the generation of three-dimensional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The company collaborates with pharmaceutical and academic partners to develop human biological disease models in three dimensions. Organovo's key instrument platform is the NovoGen Bioprinter. The firm's 3-D bioprinting technologies create tissues using living cells and biocompatible hydrogels.

Executives

David Gobel	director	440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Vaidehi Joshi	director	C/O ORGANOVO HOLDINGS, INC., 11555 SORRENTO VALLEY ROAD, SUITE 100, SAN DIEGO CA 92121
Alison Tjosvold Milhous	director	440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Adam K Stern	director	STERN AEGIS VENTURES, 810 7TH AVENUE 22ND FLOOR, NEW YORK NY 10019
Thomas Hess	officer: President, CFO and PFO	366 MADISON AVE. 12TH FLOOR, NEW YORK NY 10017
Douglas Jay Cohen	director	440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Thomas E Jurgensen	officer: General Counsel & Secretary	440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Jeffrey N. Miner	officer: Chief Scientific Officer	440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Chris Heberlig	officer: President and CFO	C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Keith Murphy	director, officer: Executive Chairman	6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Steven George Hughes	officer: Chief Medical Officer	6275 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Carolyn Beaver	director	3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
David Shapiro	director	C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES ST., NEW YORK NY 10013
Presnell Sharon Collins	officer: EVP, Research & Development	6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Taylor Crouch	director, officer: CEO & President	440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075